Table 3.
List of clinical trial results for UCAR therapies based on other cell types. Updated till 07/04/2024.
| Title | Safety assessment population (N) | CRSN (%) | ICANSN (%) | InfectionsN (%) | GVHDN (%) | Efficacy assessment population (N) | ORRN (%) | CRN (%) | Sponsor | Strategies | Target | Indication | phase of study | Location |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other T cell subtypes | ||||||||||||||
| ADI-001[63] | 9 | Gr I- II: 2(22) | Gr I: 1(11) | ≥Gr III: 1(11) | absent | 9 | 7(78) | 7(78) | Adicet Bio | γδ T | CD20 | r/r B-cell NHL | Phase 1 | US |
| KUR-502[64] | NHL (n = 5) and ALL (n = 2) | Gr I: 2/2(100) in ALL group | absent | – | absent | NHL (n = 5) and ALL (n = 2) | 4(57) | 3(43) | Athenex | iNKT cell, IL15, and short hairpin RNA expression (downregulates HLA I, II) | CD19 | r/r B-Cell Malignancies | Phase 1 | US |
| CAR EBV-CTL [65] | 16 | absent | absent | – | 3 | – | – | – | Memorial Sloan Kettering Cancer Center | EBV virus specific T cell | CD19 | r/r B-Cell Malignancies | Phase 1 | US |
| CD30. CAR-EBVST cells [66] | 14 | Gr I: 4 (28.5) | – | – | absent | 14 | 9 (69.2) | 5 (38.5) | Baylor College of Medicine | EBV virus specific T cell | CD30 | CD30-Positive Lymphoma | Phase I/II trial | US |
| CD19CAR/virus specific T cells [67] | 6 | absent | absent | – | absent | 6 | 2 (33.3) | 2 (33.3) | Baylor College of Medicine | Virus specific T cells | CD19 | CD19+B cell malignancies | Phase 1 | US |
| RJMty19[68] | 12 | Gr I /II: 4 (33.3) | absent | 1 (8.3) | absent | 5 | 3(25) | 1 (8.3) | Zhejiang University | DNT cells | CD19 | r/r B-cell NHL | Phase 1 | China |
| UCAR-NK | ||||||||||||||
| iC9/CAR.19/IL15-Transduced CB-NK Cells [69] | 11 | absent | absent | GrI: 2 (18.1) GrIII:1 (9.1) | absent | 11 | 8(73) | 7(64) | M.D. Anderson Cancer Center | NK cells; iCasp9-based safety switch gene; IL-15 | CD19 | r/r B-cell lymphoma or leukemia | Phase 1 | US |
| NKX101[70] | 6 | absent | absent | 3(50) | absent | 6 | – | 3(50) | Nkarta | NK cells | NKG2D | Acute Myeloid Leukemia (AML) | Phase 1 | US |
| AFM13-NK [71] | 42 | absent | absent | – | absent | 42 | 39 (92.8) | 28 (66.7) | M.D. Anderson Cancer Center | NK cells; combined with AFM13 (a CD30/CD16A bispecific antibody) | CD30 | Refractory CD30-Positive Lymphomas | Phase 1 | US |
| Cnty-101[28] | 1 | absent | absent | – | – | 1 | – | 1(100) | Century Therapeutics | iPSC-derived NK cells, IL-15, EGFR safety switch, and Alloevasion ™ edits (B2 M and CIITA knockouts, and HLA-E knock-in) | CD19 | r/r NHL | Phase 1 | US |
| CAR19/IL-15[72] | 37 | Gr I: 1 (2.7) | absent | Gr I-II: 7 (18.9); Gr III:8 (21.6) | absent | 37 | 18 (48.6) | 14 (37.8) | M.D. Anderson Cancer Center | Cord blood-derived NK cells, IL-15, iCasp9-based safety switch gene | CD19 | B Lymphoid Malignancies | Phase 1/2 | US |